2021 Generic and Specialty Drug Companies: Capabilities, Goals and Strategies
In the dynamic and fragmented Generic and Specialty Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.
Our collection of strategic assessments of leading Generic and Specialty Drug companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs. The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions.
The reports will also assist current competitors and potential market entrants in evaluating prospective acquisitions and joint venture candidates.
Our collection of strategic assessments of leading Generic and Specialty Drug companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs. The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions.
- Aurora Cannabis
- Canopy Growth
- Cronos Group
- Curaleaf
- Dr. Reddy's Laboratories
- Green Thumb
- Merck
- MomentaPharma
- Mylan
- Perrigo
- Teva Pharma
- Tilray
- oetis
The reports will also assist current competitors and potential market entrants in evaluating prospective acquisitions and joint venture candidates.
More Publications
2019 Pharmaceutical Competitive Intelligence: Endo Pharmaceuticals Performance, Capabilities, Goals and Strategies
US$ 950.00
February 2019
-
2019 Pharmaceutical Market Consolidation: Who will not survive?
US$ 6,500.00
February 2019
-
Animal Health Market Forecast 2017-2021: Accelerated Rate of Change and Regulatory Uncertainty Confronting the Industry--Performance, Capabilities, Goals and Strategies of Leading Animal Health Companies
US$ 3,850.00
December 2017
110 pages
Phibro 2019: Business Challenges, Technological Capabilities, Marketing Tactics, Strategic Direction
US$ 450.00
June 2019
-
2020 Canopy Growth Performance, Capabilities, Goals and Strategies
US$ 950.00
March 2020
-
